Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$20.62
-5.0%
$24.30
$20.42
$53.96
$972.03M0.72499,250 shs430,237 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$9.02
-4.0%
$11.24
$6.36
$47.45
$1.03B1.081.91 million shs1.58 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$29.41
-1.1%
$25.63
$16.16
$31.80
$1.19B0.75224,061 shs353,024 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$5.69
-3.1%
$7.38
$3.50
$14.30
$268.40MN/A351,668 shs19,371 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
+2.02%-2.30%-15.27%-7.07%-44.95%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.75%+6.82%-13.44%+15.06%-77.34%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-2.65%-4.53%+21.60%+71.95%+56.31%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
+8.50%-12.39%-22.15%-41.65%+586,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.3182 of 5 stars
3.12.00.03.71.94.21.3
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.8979 of 5 stars
4.53.00.00.03.04.20.0
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.0499 of 5 stars
0.94.02.51.13.33.32.5
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3356.81% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.00
Buy$40.63350.39% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-17.04% Downside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZYBT, AMPH, DYN, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.00
7/11/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/26/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/25/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/24/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$13.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.00
6/17/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.33$4.85 per share4.25$15.23 per share1.35
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.17$2.04 per share14.45$6.34 per share4.64
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$25.53M10.51$0.11 per share52.50N/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.767.476.275.5419.38%22.20%10.40%8/6/2025 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7837.7114.000.512.68%30.51%6.89%8/27/2025 (Estimated)
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A

Latest ZYBT, AMPH, DYN, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.99N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.71N/AN/AN/A$173.42 millionN/A
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.63%N/A61.54%N/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A

Latest ZYBT, AMPH, DYN, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
20.35
20.35
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.18 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million97.59 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
27847.17 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology Holding Ltd
ZYBT Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited (ZYBT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$20.62 -1.08 (-4.98%)
Closing price 04:00 PM Eastern
Extended Trading
$20.62 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$9.02 -0.38 (-4.04%)
Closing price 04:00 PM Eastern
Extended Trading
$9.16 +0.15 (+1.61%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$29.44 +0.03 (+0.10%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$5.69 -0.18 (-3.07%)
As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.